Prerpints.org logo
Preprint
Review

Monkeypox: Re-emerging Infectious Disease and One Health Strategy

Altmetrics

Downloads

351

Views

245

Comments

0

This version is not peer-reviewed

Submitted:

04 May 2023

Posted:

06 May 2023

You are already at the latest version

Alerts
Abstract
World Health Organization (WHO) has announced the monkeypox (MPX) epidemic a global public health emergency due to its re-emergence, remarkable increase in the number of MPX cases worldwide, and its potential spread. This paper introduces the symptoms, complications, and features of MPX; its transmission, diagnosis and testing, vaccines and treatment; MPX and sexually transmitted diseases, especially the human immunodeficiency virus (HIV); possible natural hosts or reservoirs of the monkeypox virus (MPXV). A useful tool for MPX and surgical safety recommendations are presented. The challenges in fighting the MPX epidemic, One Health strategy, and future research are discussed.
Keywords: 
Subject: Public Health and Healthcare  -   Public Health and Health Services

1. Introduction

A global MPX outbreak began in 2022. In May 2022, at least 640 suspected or confirmed MPX cases in 36 countries on various continents were documented [1]. Since the end of June 2022, there has been a remarkable increase in the number of MPX cases in the global. WHO has declared the MPX epidemic a worldwide public health emergency due to its re-emergence, re-emerging health threat, and potential spread [2]. By July 21, 2022, WHO declared 15,734 laboratory confirmed MPX infection cases in 75 countries on five continents. But the number of cases is probably an underestimate of the real infection number because of insufficient clinical verification of MPXV infections as well as a long virus incubation period (5–21 days) [3].
The first outbreak of MPXV infections was documented in monkeys in Denmark in 1959 [4]. The name monkeypox was therefore derived from the historical fact that the viral disease was reported in research monkeys in a Danish laboratory [5]. MPXV was first recognized as a human pathogen in the Democratic Republic of the Congo in 1970. Two genetic clades of MPXV have been identified: Central African and Western African. The first clade has a larger fatality rate and more human-to-human transmissions compared with the second clade [6]. MPX crossed the boundaries from Africa, and 70 cases of MPX infection related to infected pet prairie dogs were documented in the US in 2003. Then cases of MPX infection were declared in Israel (2018), the United Kingdom (UK) (2018, 2019, 2021, and 2022), Singapore (2019), the USA again (2021), etc. Between May 7 and 25, 2022, 86 cases of MPX infection were reported in the UK (79 cases being male and 66 cases being bisexual, gay, or other men who had sex with men) [7,8].
MPXV is an orthopoxvirus and Chordopoxvirinae and a close subgroup of variola viruses (smallpox) [9]. Smallpox is highly transmissible, and its mortality rate is approximately 30%. After a great vaccination campaign, it was announced eradicated in 1980; therefore, regular smallpox vaccination stopped [10]. MPX was endemic in Central and West African countries. It can be controlled and eliminated in a semi-endemic equilibrium through vaccination. But in a fully- endemic equilibrium, it cannot be stopped through only vaccination [11,12].
MPXV is an enveloped and double-stranded DNA virus of the genus orthopoxvirus and family Poxviridae. It can infect and be found in non-human primates, African squirrels, and rodents [13,14]. In the MPX cases of USA, 99% happened in men with 94% of the men being infected due to male-to-male sexual or close intimate contact. Clinical signs differed from typical MPX (fewer people with prodrome and more people with genital rashes) [15].
MPXV leads to human monkeypox (human MPX), a neglected tropical zoonotic disease in humans that is similar to smallpox. There have been many human cases of MPX in five countries in Central and West Africa since 1970. Many cases happened in tropical rainforest areas and the clustering of cases was found in certain areas within countries and within families. Human MPX was noticed after the campaign of smallpox vaccination was ended therefore, immunologically unprotected people were at risk of MPXV infection [16,17]. Human MPX was ever endemic to central and eastern Africa. A human MPXV outbreak happened in the USA in 2003 due to an import of infected African rodents [18,19,20].
The efforts in the research of this comprehensive review paper were to introduce and discuss a few important issues regarding MPX. The subsequent sections of the paper are organized as follows: the second section introduces the symptoms, complications, and features of MPX; the third section presents the transmission of MPX; the fourth section introduces the diagnosis and testing of MPX; the fifth section presents the vaccines and treatment of MPX; the sixth section deals with MPX and sexually transmitted diseases; the seventh section discusses possible natural hosts or reservoirs of MPXV; the eighth section introduces a useful tool for MPX and surgical safety recommendations; the ninth section discusses the challenges and One Health strategy; and the tenth section is the conclusion and future research.

2. Symptoms, Complications, and Features of Monkeypox

MPXV is closely associated with the infamous variola (smallpox) virus, leading to a febrile rash illness in humans that is like smallpox but milder than it [21]. MPXV brings about lymphadenopathy. The beginning of infection with MPXV is headache, backache, muscle aches, chills, fever, and fatigue [22]. After the beginning of the fever, the infected individual has a rash on the face, then diffusion to other parts of the body. Lesions begin within the oropharynx, then spread throughout the body [23]. Common (nonspecific) symptoms and complications of MPX are shown in Table 1 [24]. A feature rash grows into papules, vesicles, and pustules that ultimately scab over and are healed [25].
Core clinical features of human MPX are rash, fatigue, fever, lesions, respiratory symptoms, and lymphadenopathy [26]. Human MPX can be severe for pregnant women, children, and immune-compromised people. The fatality rate of these people is approximately 3–6% [27]. For pregnant women, MPXV could be transmitted through the placenta and cause fetal death [25]. Atypical manifestations that may be related to the body site of viral entry, urge a low threshold for the clinical suspicion of MPX, especially in the situation with a large transmission rate or in individuals who are at a high-level risk of contagion [28]. A long-term complication of MPX is vision loss due to the infection of the eye cornea and tissue scarring [29]. Dental care workers ought to be aware that premonitory manifestations of MPX are generally on the oral mucosa as macules and ulcers before typical skin lesions [30].
The mortality rate of MPX varies with the patient’s age, the virus clade, and the outbreak place. The mortality of MPX is generally higher for young adults, children, and immunocompromised individuals. It is like smallpox that MPX is generally more fatal for children than adults [9,25]. In humans, the MPXV infection starts with an incubation period, then a prodrome of fever, disseminated skin lesions (growing from macules to papules, vesicles, and pustules), and scabbing [31]. An MPX outbreak in the USA demonstrated that the incubation interval is various. The incubation period depends on the nature and route of exposure (such as wild animals, infected pets, or infected people). The household attack rate was defined as the rate of persons living with an infected individual and developing the MPX symptoms. An analysis was conducted on the infection dynamics of MPXV, and it showed a 50% of household attack rate (on average) which is much higher than the published result [32]. Table 2 summarized the features of MPX.

3. Transmission of Monkeypox

Modes of transmission of MPXV include fomites, respiratory, direct contact with infected animals or humans, and eating infected meats [26]. There are two types of MPXV transmission: animal–human transmission (also called zoonotic transmission) and human–human transmission [39,40]. MPX transmits somewhat inefficiently from person to person. MPXV can be transmitted from pregnant ladies to fetuses by the placenta, or from infected parents to their children by skin contact after or during the birth of children [41].
Both smallpox and MPX are thought to be transmitted among humans mainly through respiratory secretions [42]. Clinical samples were collected b real-time PCR; MPX DNA was found in saliva and skin lesions in all cases; and there were great viral loads in some of the cases, especially in the skin pustules. Most samples in the following sample types are positive: nasopharyngeal swab, rectal swab, urine, semen, and feces. This is valuable information regarding virus shedding and the possible role of body fluids in MPX transmissions [43]. Table 3 [24] shows the suspected transmission modes of MPX to humans. The reproductive number (denoted as R 0 ) of MPXV for the Central African clade has been assessed and it ranges 0.6-1.0. The R 0 for the West African clade of MPXV has not been assessed; however, it has thought to be less than that of the Central African clade. [44,45].

4. Diagnosis and Testing

Whole genome sequencing is a gold standard used to distinguish MPXV from other orthopoxviral, but it is limited in some areas because it is very costly. Loop-mediated isothermal amplification technology, restriction length fragment polymorphism, and recombinase polymerase amplification have been developed for MPXV DNA detection [46]. Diagnosis is primarily clinical; however, laboratory testing is required for a conclusive diagnosis [47].
PCR is a preferred laboratory testing method in clinical diagnosis owing to its high sensitivity and accuracy. The serology and antigen detection approaches are not suggested due to their cross-reactivity. The ideal samples for MPX testing are skin lesions, dry crusts, and fluid from vesicles and pustules [48]. Table 4 [49] shows diagnostic tests for MPXV or orthopoxviral (OPXV). Real-time PCR (RT-PCR) is the desired testing method for detecting MPXV during acute infections [50]. Diagnostic methods of identifying human MPX and their pros/cons are shown in Table 5 [51]. They work better if they are integrated with medical and epidemiological information such as patient immunization history.

5. Vaccines and Treatment

There is no specific vaccine for MPXV. Vaccines for the prevention of MPX in high-risk groups or post-exposure prophylaxis are still smallpox-specific vaccines. The use of smallpox vaccine for MPX prevention is still mainly restricted to high-risk groups or health personnel who treat MPX, but mass vaccination against MPX has not been required or recommended [2]. Many patients infected with MPX have mild symptoms and can recover without any medical treatment [52].
The vaccination of humans with LC16m8 has long-term protection against MPX. LC16m8 is a highly attenuated smallpox vaccine that was developed in Japan. Although smallpox has been eradicated, it is possible for it to re-emerge in the future. Therefore, the smallpox vaccine such as LC16m8 is still necessary not only for the protection of people in the human MPX-endemic regions from human MPX but also for stockpiling in preparation for a possible future outbreak of smallpox [18]. In the USA and Canada, the modified vaccinia Ankara vaccine (MVA-BN; Bavarian Nordic, Denmark) has been licensed for adults infected with smallpox or MPX [3].
IMVAMUNE is the third-generation smallpox vaccine. It has been used in people infected with HIV as well as individuals with atopic dermatitis. It has been purchased for the U.S. Strategic National Stockpile (SNS) for use under an Emergency Use Authorization. Table 6 shows its features [53]. Third-generation vaccines are now feasible in preventing MPX. There is no licensed antiviral drug for MPX, but it has been proven that antiviral drugs used for smallpox are also useful for patients infected with MPX. As of January 2022, Tecovirimat (also known as TPOXX) has been authorized in treating MPX [47,48].

6. Monkeypox and Sexually Transmitted Diseases

MPX lesions are susceptible to bacterial superinfection. In the recent MPX outbreak, most cases were recognized in men who had sex with men (MSM), leading to a vesicular–pustular rash or genital lesions. The rash usually appears on the perineal area and genitals, indicating that the transmission due to sexual intercourse can easily be confused with other sexually transmitted diseases [54]. Examinations revealed proctitis, as well as anal and rectal ulcers with the detection of MPXV, indicating that sexual transmission plays a role in the MPX outbreak [55]. Sexual contact has been regarded as a probable route of human spread, particularly male-to-male contact [41].
Notable MPX incidents were recognized among gays, bisexuals, and MSM [56]. Sexual activities, mostly among gays or bisexual men, were the most often suspected route of human MPX transmission. Documents of clusters related to sex parties or saunas highlight the prospective role of sexual contacts as a transmission supporter. International travels and participation in big gatherings linked to sex-onsite activities might justify the worldwide spread of MPX through the sexual network [57]. MPX spread among MSM has been a major concern; however, heterosexual intercourse could not be ignored [44].
The overlapping of MPX with other endemic transmissible diseases in the globe such as HIV infection, measles, malaria, orthohantavirus, arboviral diseases, etc. has led to a worse complex scenario, especially for unvaccinated children [27]. Immunodeficiency may lead to worse clinical outcomes of an MPX infection. An advanced or poorly virally controlled HIV infection may lead to more severe outcomes after MPX infection [2]. HIV-1 infected persons have elongated MPX sickness, bigger lesions, and greater rates of secondary bacterial skin infections as well as genital ulcers [58]. HIV-positive persons can be infected with MPX independent of CD4+ count; the clinical sign is usually a large skin lesion in the genital area. Syphilis coinfection is conceivable. If a patient's CD4+ count is exceptionally low, death may happen [59]. Recommendations (United States, August 2022) for the management of people with monkeypox and HIV infection are shown in Table 7 [60].

7. Possible Natural Hosts and Reservoirs of MPXV

There is no definitive natural host or reservoir for MPXV, but rodents and non-human primates are considered as potential natural hosts and reservoirs of MPXV [39,61]. A few rodent species such as African pouched rats (Cervicectomies spp.) have been regarded as potential reservoirs [62]. The rope squirrel and the Gambian pouched rat are the most possible natural hosts of MPXV. In addition, the sooty mangabey monkey has been regarded as a suspected host of MPXV [26].
Acute MPXV infection and positive serology have been found in several animal species including non-human primates as well as small mammals. Despite the growing evidence of acute or prior infection, MPXV has been isolated from wild animals in only two situations, one from a rope squirrel and the other from a sooty mangabey [63]. Some aspects of the MPXV transmission cycle, such as the natural host of MPXV, are still unidentified. MPXV caused noteworthy pathology in African rope squirrels and infected rope squirrels shed substantial quantities of the virus, indicating their effect on the MPXV epidemiology in Central Africa as a prospective source of the MPXV transmission to humans and animals in endemic MPX zones [64].

8. A Useful Tool for Monkeypox and Surgical Safety Recommendations

Table 8 shows a prehospital adaptation of the MPX Identify-Isolate-Inform (3I) Tool with specific considerations for Emergency Medical Services (EMS) professionals [65,66]. Significant suggestions from admission to the emergency room, during surgery, hospitalization, and hospital discharge are listed in Table 9 [67].

9. Challenges and One Health Strategy

MPX can be re-emerging from time to time. The core reason of the current outbreaks should be further studied. The key issue should be disclosing the zoonotic reservoir, zoonosis, spillover of the virus from the host, etc. [68]. One of major challenges lies in that the main source of infection has not been confirmed, and the main source is a major determinant in breaking the disease transmission chain in a population [4].
Human MPX is the most noteworthy orthopoxvirus infection disease since the smallpox extermination [69]. There are challenges in handling human MPX with potential human-to-human transmission through sexual contacts. Contact tracing is difficult because some patients had sex with multiple anonymous partners. Attention among healthcare providers in nonendemic countries must be paid [70]. In addition, the vaccine acceptance of MPX remains a challenge, which is like during the COVID-19 pandemic.
Humans, animals, and environment are interconnected closely. One Health strategy is needed in fighting epidemics or pandemics of infectious diseases (such as MPX, COVID-19, and Ebola). One Health is a cross-sectoral, collaborative, and multidisciplinary approach that works at the local, regional, national, and global levels [71]. It is actually a systems engineering method. It facilitates data and knowledge sharing and unified decision-making [71], promotes resolving complicated health threats, reduces duplications among sectors[72], and improves medical supply chains management and operations.
One Health strategy should be fulfilled based on cutting-edge technologies, including Big Data analytics, blockchain, artificial intelligence (e.g., machine learning, especially deep learning), etc. During epidemics, Big Data analytics helps fix problems such as data heterogeneity, incomplete data, and geographical data merging and sharing; deep learning is powerful in the prediction of trends and infection cases of diseases. Patient information sharing can bring up privacy problems. Blockchain helps protect the privacy, improve the management of electronic medical records (EMR), facilitate pharmaceutical supply chain management, and finally enhance the cybersecurity of One Health programs.
During the spread of MPX and COVID-19, One Health strategy and programs were not developed well due to complicated reasons such as politics. Some politicians in some countries were very active in distorting facts based on their political opinions during speeches via social media, which led to high infection cases, hospitalizations, and deaths because science-based decision-making was weak. This situation brough negative effects on global cooperation and One Health.

10. Conclusion and Future Research

MPX is a zoonotic disease milder than smallpox and has a mortality rate higher in young adults, children, and immunocompromised patients compared with other people. RT-PCR is the preferred test of MPXV during acute infection. Smallpox-specific vaccines are still used for the prevention of MPX in high-risk groups or post-exposure prophylaxis. Sexual contact, especially MSM, is a potential route of human spread; heterosexual intercourse should not be ignored. HIV infection can lead to more severe outcomes after MPX infection. The natural host or reservoir for MPXV has not been confirmed, but rodents and non-human primates are potential natural hosts or reservoirs. There are challenges in vaccine acceptance and handling human MPX with potential human-to-human transmission through sexual contacts due to difficult contact tracing.
One Health strategy is required in fighting MPX, COVID-19, Ebola, etc. Big Data analytics, deep learning, blockchain, etc. help fulfill One Health strategy and enhance the cybersecurity of One Health programs. All the challenges listed in this paper can be future research topics. We will focus on the predictive modelling of MPX using Big Data analytics and deep learning and blockchain-based cybersecurity for One Health.

Author Contributions

Cheryl Ann Alexander: Conceptualization, writing. Lidong Wang: resources, writing - tables.

Acknowledgments

The authors appreciate the support from Technology & Healthcare Solutions, USA.

Conflicts of Interest

Authors declare no conflict of interest.

References

  1. Rahimi, F., & Abadi, A. T. B. (2022). The 2022 monkeypox outbreak: Lessons from the 640 cases in 36 countries. International journal of surgery (London, England), 104, 106712. [CrossRef]
  2. Liu, X., Zhu, Z., Miao, Q., Lim, J. W., & Lu, H. (2022). Monkeypox–A danger approaching Asia. BioScience Trends, 16(4), 245-248. [CrossRef]
  3. Vouga, M., Nielsen-Saines, K., Dashraath, P., & Baud, D. (2022). The monkeypox outbreak: risks to children and pregnant women. The Lancet Child & Adolescent Health, 6(11), 751-753. [CrossRef]
  4. Idris, I., & Adesola, R. O. (2022). Current efforts and challenges facing responses to Monkeypox in United Kingdom. Biomedical journal. 2022 Aug 5:S2319-4170(22)00118-4. [CrossRef]
  5. Thakur, V., Thakur, P., Srivastava, S., & Kumar, P. (2022). Monkeypox virus (MPX) in humans a concern: Trespassing the global boundaries–Correspondence. International Journal of Surgery (London, England), 104, 106703. [CrossRef]
  6. Jamil, H., Tariq, W., Tahir, M. J., Mahfooz, R. S., Asghar, M. S., & Ahmed, A. (2022). Human monkeypox expansion from the endemic to non-endemic regions: Control measures. Annals of Medicine and Surgery, 79, 104048. [CrossRef]
  7. Monkeypox (n.d.), https://www.who.int/news-room/fact-sheets/detail/monkeypox (accessed May 21, 2022).
  8. Vivancos, R., Anderson, C., Blomquist, P., Balasegaram, S., Bell, A., Bishop, L., ... & Hopkins, S. (2022). Community transmission of monkeypox in the United Kingdom, April to May 2022. Eurosurveillance, 27(22), 2200422. [CrossRef]
  9. Fatima, N., & Mandava, K. (2022). Monkeypox-a menacing challenge or an endemic?. Annals of Medicine and Surgery, 79, 103979. [CrossRef]
  10. Hutson, C. L., Kondas, A. V., Mauldin, M. R., Doty, J. B., Grossi, I. M., Morgan, C. N., ... & Olson, V. A. (2021). Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model. MSphere, 6(1), e00927-20. [CrossRef]
  11. Matias, W. R., Koshy, J. M., Nagami, E. H., Kovac, V., Moeng, L. R., Shenoy, E. S., ... & Lazarus, J. E. (2022, August). Tecovirimat for the treatment of human monkeypox: an initial series from Massachusetts, United States. In Open Forum Infectious Diseases (Vol. 9, No. 8, p. ofac377). Oxford University Press. [CrossRef]
  12. Bankuru, S. V., Kossol, S., Hou, W., Mahmoudi, P., Rychtář, J., & Taylor, D. (2020). A game-theoretic model of Monkeypox to assess vaccination strategies. PeerJ, 8, e9272. [CrossRef]
  13. Fenner, F.; Wittek, R.; Dumbell, K.R. Chapter 8. Monkeypox Virus. The Orthopoxviruses, Academic Press, San Diego, 1989, pp. 227–267.
  14. World Health Organization, Monkeypox, 2022. Available from: https://www.who. int/news-room/fact-sheets/detail/monkeypox. (Accessed 30 May 2022).
  15. Philpott, D. (2022). Epidemiologic and clinical characteristics of monkeypox cases—United States, May 17–July 22, 2022. MMWR. Morbidity and Mortality Weekly Report, 71.
  16. Franceschi, V., Parker, S., Jacca, S., Crump, R. W., Doronin, K., Hembrador, E., ... & Donofrio, G. (2015). BoHV-4-based vector single heterologous antigen delivery protects STAT1 (-/-) mice from monkeypoxvirus lethal challenge. PLoS neglected tropical diseases, 9(6), e0003850. [CrossRef]
  17. Martín-Delgado, M. C., Martín Sánchez, F. J., Martínez-Sellés, M., Molero García, J. M., Moreno Guillén, S., Rodríguez-Artalejo, F. J., ... & Bouza, E. (2022). Monkeypox in humans: a new outbreak. Rev Esp Quimioter, 35(6), 509-518. [CrossRef]
  18. Iizuka, I., Ami, Y., Suzaki, Y., Nagata, N., Fukushi, S., Ogata, M., ... & Saijo, M. (2017). A single vaccination of nonhuman primates with highly attenuated smallpox vaccine, LC16m8, provides long-term protection against monkeypox. Japanese Journal of Infectious Diseases, 70(4), 408-415. [CrossRef]
  19. Hutson, C. L., Gallardo-Romero, N., Carroll, D. S., Clemmons, C., Salzer, J. S., Nagy, T., ... & Damon, I. K. (2013). Transmissibility of the monkeypox virus clades via respiratory transmission: investigation using the prairie dog-monkeypox virus challenge system. PLoS One, 8(2), e55488. [CrossRef]
  20. Mauldin, M. R., McCollum, A. M., Nakazawa, Y. J., Mandra, A., Whitehouse, E. R., Davidson, W., ... & Reynolds, M. G. (2022). Exportation of monkeypox virus from the African continent. The Journal of infectious diseases, 225(8), 1367-1376. [CrossRef]
  21. Xiang, Y., & White, A. (2022). Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters. Emerging microbes & infections, 11(1), 1768-1777. [CrossRef]
  22. Kumar, N., Acharya, A., Gendelman, H. E., & Byrareddy, S. N. (2022). The 2022 outbreak and the pathobiology of the monkeypox virus. Journal of Autoimmunity, 102855. [CrossRef]
  23. Moore M., Monkeypox, Publishing ISITIFS, vol. 22, National Library of Medicine, Monkeypox, 2022, May.
  24. Kaler, J., Hussain, A., Flores, G., Kheiri, S., & Desrosiers, D. (2022). Monkeypox: a comprehensive review of transmission, pathogenesis, and manifestation. Cureus, 14(7). [CrossRef]
  25. Kmiec, D., & Kirchhoff, F. (2022). Monkeypox: a new threat?. International journal of molecular sciences, 23(14), 7866. [CrossRef]
  26. Brown, K., & Leggat, P. A. (2016). Human monkeypox: current state of knowledge and implications for the future. Tropical medicine and infectious disease, 1(1), 8. [CrossRef]
  27. Rouhani, J., & Keikha, M. (2022). The past, present, and future of a silent multi-country human monkeypox outbreak 2022–Correspondence. International Journal of Surgery (London, England), 104, 106817. [CrossRef]
  28. Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., ... & Mitjà, O. (2022). Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. The Lancet, 400(10353), 661-669. [CrossRef]
  29. Jezek, Z.; Szczeniowski, M.; Paluku, K.M.; Mutombo, M. Human Monkeypox: Clinical Features of 282 Patients. J. Infect. Dis. 1987, 156, 293–298. [CrossRef]
  30. Samaranayake, L., & Anil, S. (2022). The monkeypox outbreak and implications for dental practice. international dental journal. [CrossRef] [PubMed] [PubMed Central]
  31. Weiner, Z. P., Salzer, J. S., LeMasters, E., Ellison, J. A., Kondas, A. V., Morgan, C. N., ... & Hutson, C. L. (2019). Characterization of Monkeypox virus dissemination in the black-tailed prairie dog (Cynomys ludovicianus) through in vivo bioluminescent imaging. Plos one, 14(9), e0222612. [CrossRef]
  32. Nolen, L. D., Osadebe, L., Katomba, J., Likofata, J., Mukadi, D., Monroe, B., ... & Reynolds, M. G. (2016). Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerging infectious diseases, 22(6), 1014. [CrossRef]
  33. Beer, E. M., & Rao, V. B. (2019). A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS neglected tropical diseases, 13(10), e0007791. [CrossRef]
  34. Jezek, Z., Grab, B., Paluku, K. M., & Szczeniowski, M. V. (1988). Human monkeypox: disease pattern, incidence and attack rates in a rural area of northern Zaire. Tropical and geographical medicine, 40(2), 73-83. [PubMed]
  35. Panning, M., Asper, M., Kramme, S., Schmitz, H., & Drosten, C. (2004). Rapid detection and differentiation of human pathogenic orthopox viruses by a fluorescence resonance energy transfer real-time PCR assay. Clinical chemistry, 50(4), 702-708. [CrossRef] [PubMed]
  36. Neubauer, H., Reischl, U., Ropp, S., Esposito, J. J., Wolf, H., & Meyer, H. (1998). Specific detection of monkeypox virus by polymerase chain reaction. Journal of virological methods, 74(2), 201-207. [CrossRef] [PubMed]
  37. Li, Y., Olson, V. A., Laue, T., Laker, M. T., & Damon, I. K. (2006). Detection of monkeypox virus with real-time PCR assays. Journal of Clinical Virology, 36(3), 194-203. [CrossRef] [PubMed]
  38. Adalja, A., & Inglesby, T. (2022). A novel international monkeypox outbreak. Annals of Internal Medicine. [CrossRef] [PubMed]
  39. Alakunle, E., Moens, U., Nchinda, G., & Okeke, M. I. (2020). Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. Viruses, 12(11), 1257. [CrossRef]
  40. Peter, O. J., Kumar, S., Kumari, N., Oguntolu, F. A., Oshinubi, K., & Musa, R. (2022). Transmission dynamics of Monkeypox virus: a mathematical modelling approach. Modeling Earth Systems and Environment, 8(3), 3423-3434. [CrossRef]
  41. Zhu, M., Ji, J., Shi, D., Lu, X., Wang, B., Wu, N., ... & Li, L. (2022). Unusual global outbreak of monkeypox: what should we do?. Frontiers of medicine, 1-11. [CrossRef]
  42. Hutson, C. L., Carroll, D. S., Gallardo-Romero, N., Weiss, S., Clemmons, C., Hughes, C. M., ... & Damon, I. K. (2011). Monkeypox disease transmission in an experimental setting: prairie dog animal model. PLoS One, 6(12), e28295. [CrossRef]
  43. Peiró-Mestres, A., Fuertes, I., Camprubí-Ferrer, D., Marcos, M. Á., Vilella, A., Navarro, M., ... & Hospital Clinic de Barcelona Monkeypox Study Group. (2022). Frequent detection of monkeypox virus DNA in saliva, semen, and other clinical samples from 12 patients, Barcelona, Spain, May to June 2022. Eurosurveillance, 27(28), 2200503. [CrossRef]
  44. Quarleri, J., Delpino, M., & Galvan, V. (2022). Monkeypox: considerations for the understanding and containment of the current outbreak in non-endemic countries. Geroscience, 44(4), 2095-2103. [CrossRef]
  45. Rimoin, A. W., Mulembakani, P. M., Johnston, S. C., Lloyd Smith, J. O., Kisalu, N. K., Kinkela, T. L., ... & Muyembe, J. J. (2010). Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences, 107(37), 16262-16267. [CrossRef]
  46. Gong, Q., Wang, C., Chuai, X., & Chiu, S. (2022). Monkeypox virus: a re-emergent threat to humans. Virologica Sinica. 2022 Aug;37(4):477-482. [CrossRef]
  47. Weinstein, R. A., Nalca, A., Rimoin, A. W., Bavari, S., & Whitehouse, C. A. (2005). Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clinical infectious diseases, 41(12), 1765-1771. [CrossRef]
  48. Yang, Z. S., Lin, C. Y., Urbina, A. N., Wang, W. H., Assavalapsakul, W., Tseng, S. P., ... & Wang, S. F. (2022). The first case of monkeypox virus infection detected in Taiwan: awareness and preparation. International Journal of Infectious Diseases, 122, 991-995. [CrossRef]
  49. McCollum, A. M., & Damon, I. K. (2014). Human monkeypox. Clinical infectious diseases, 58(2), 260-267. [CrossRef] [PubMed]
  50. WHO, Monkeypox. 2022.
  51. Hraib, M., Jouni, S., Albitar, M. M., Alaidi, S., & Alshehabi, Z. (2022). The outbreak of monkeypox 2022: An overview. Annals of Medicine and Surgery, 104069. [CrossRef]
  52. Rizk, J. G., Lippi, G., Henry, B. M., Forthal, D. N., & Rizk, Y. (2022). Prevention and treatment of monkeypox. Drugs, 1-7. [CrossRef]
  53. Petersen, B. W., Kabamba, J., McCollum, A. M., Lushima, R. S., Wemakoy, E. O., Tamfum, J. J. M., ... & Reynolds, M. G. (2019). Vaccinating against monkeypox in the Democratic Republic of the Congo. Antiviral research, 162, 171-177. [CrossRef]
  54. Ortiz-Martínez, Y., Rodríguez-Morales, A. J., Franco-Paredes, C., Chastain, D. B., Gharamti, A. A., Vargas Barahona, L., & Henao-Martínez, A. F. (2022). Monkeypox–a description of the clinical progression of skin lesions: a case report from Colorado, USA. Therapeutic Advances in Infectious Disease, 9, 20499361221117726. [CrossRef]
  55. Pfäfflin, F., Wendisch, D., Scherer, R., Jürgens, L., Godzick-Njomgang, G., Tranter, E., ... & Schürmann, D. (2022). Monkeypox in-patients with severe anal pain. Infection, 1-5. [CrossRef]
  56. Mahase, E. (2022). Monkeypox: What do we know about the outbreaks in Europe and North America? [CrossRef]
  57. Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., ... & Orkin, C. M. (2022). Monkeypox virus infection in humans across 16 countries—April–June 2022. New England Journal of Medicine, 387(8), 679-691. [CrossRef]
  58. Ogoina, D., Iroezindu, M., James, H. I., Oladokun, R., Yinka-Ogunleye, A., Wakama, P., ... & Ihekweazu, C. (2020). Clinical course and outcome of human monkeypox in Nigeria. Clinical Infectious Diseases, 71(8), e210-e214. [CrossRef]
  59. Mungmunpuntipantip, R., & Wiwanitkit, V. (2022). Monkeypox in HIV Infected Cases: A Summary on Clinical Presentation of 27 Cases. Infection & Chemotherapy, 54(3), 549-550. [CrossRef]
  60. O’Shea, J. (2022). Interim guidance for prevention and treatment of monkeypox in persons with HIV infection—United States, August 2022. MMWR. Morbidity and Mortality Weekly Report, 71.
  61. Rao, A. K., Schulte, J., Chen, T. H., Hughes, C. M., Davidson, W., Neff, J. M., ... & Nolen, L. D. (2022). Monkeypox in a traveler returning from Nigeria—Dallas, Texas, July 2021. Morbidity and Mortality Weekly Report, 71(14), 509.
  62. Hutson, C. L., Nakazawa, Y. J., Self, J., Olson, V. A., Regnery, R. L., Braden, Z., ... & Carroll, D. S. (2015). Laboratory investigations of African pouched rats (Cricetomys gambianus) as a potential reservoir host species for monkeypox virus. PLoS neglected tropical diseases, 9(10), e0004013. [CrossRef]
  63. Haider, N., Guitian, J., Simons, D., Asogun, D., Ansumana, R., Honeyborne, I., ... & Zumla, A. (2022). Increased outbreaks of monkeypox highlight gaps in actual disease burden in Sub-Saharan Africa and in animal reservoirs. International Journal of Infectious Diseases. [CrossRef]
  64. Falendysz, E. A., Lopera, J. G., Doty, J. B., Nakazawa, Y., Crill, C., Lorenzsonn, F., ... & Rocke, T. E. (2017). Characterization of Monkeypox virus infection in African rope squirrels (Funisciurus sp.). PLoS neglected tropical diseases, 11(8), e0005809. [CrossRef]
  65. Koenig, K. L., Beÿ, C. K., & Marty, A. M. (2022). Monkeypox 2022: a primer and identify-isolate-inform (3I) tool for Emergency Medical Services professionals. Prehospital and Disaster Medicine, 37(5), 687-692. [CrossRef]
  66. Koenig, K. L., Beÿ, C. K., & Marty, A. M. (2022). Monkeypox 2022 Identify-Isolate-Inform: A 3I Tool for frontline clinicians for a zoonosis with escalating human community transmission. One Health, 15, 100410. [CrossRef]
  67. Alvarado, G. A. D., Hernández, J. A. R., Moreno, A. F. H., Orozco, J. M. E., Cotamo, J. J. R., Gómez, L. E. L., & Gómez, S. S. (2022). Monkeypox outbreak, will it affect surgery services?–Correspondence. International Journal of Surgery (London, England). [CrossRef]
  68. Bhattacharya, M., Dhama, K., & Chakraborty, C. (2022). Recently spreading human monkeypox virus infection and its transmission during COVID-19 pandemic period: A travelers' prospective. Travel Medicine and Infectious Disease, 49, 102398. [CrossRef]
  69. Osadebe, L., Hughes, C. M., Shongo Lushima, R., Kabamba, J., Nguete, B., Malekani, J., ... & McCollum, A. M. (2017). Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo. PLoS Neglected Tropical Diseases, 11(9), e0005857. [CrossRef]
  70. Mileto, D., Riva, A., Cutrera, M., Moschese, D., Mancon, A., Meroni, L., ... & Antinori, S. (2022). New challenges in human monkeypox outside Africa: A review and case report from Italy. Travel medicine and infectious disease, 102386. [CrossRef]
  71. Islam, M. M., Dutta, P., Rashid, R., Jaffery, S. S., Islam, A., Farag, E., ... & Hassan, M. M. (2023). Monkeypox at the human-animal-ecology interface: a comprehensive review of viral characteristics, transmission, pathobiology, prevention, and control strategies. Virulence,14(1): 2186357. [CrossRef]
  72. Kelly, T. R., Machalaba, C., Karesh, W. B., Crook, P. Z., Gilardi, K., Nziza, J., ... & Mazet, J. A. (2020). Implementing One Health approaches to confront emerging and re-emerging zoonotic disease threats: lessons from PREDICT. One Health Outlook, 2, 1-7. [CrossRef]
Table 1. Common symptoms and complications of MPX.
Table 1. Common symptoms and complications of MPX.
Common symptoms Complications
  • Headache
  • Backache
  • Chills
  • Fever
  • Rashes
  • Exhaustion
  • Myalgia
  • Mouth & throat ulcers
  • Lymphadenopathy
  • Respiratory distress
  • Dehydration
  • Bacterial superinfection
  • Cellulitis
  • Encephalitis
  • Sepsis & septic shock
  • Bronchopneumonia
  • Corneal infection/permanent scarring
Table 2. Features of MPX [25,30,33,34,35,36,37,38].
Table 2. Features of MPX [25,30,33,34,35,36,37,38].
Aspects of features Description
Contagiousness High
Fatality From 1 to 10% based on the clade of the infecting MPXV strain and the healthcare availability; 3% to 6% due to a severe disease caused by some strains (WHO reported), less than smallpox (up to 30%).
Spread Respiratory droplets, close contact, and contact with skin lesions or newly contaminated items.
Incubation period 5-21 days (on average 7-14 days).
Agent Monkeypox virus
Sickness Mild sickness with swollen lymph nodes (lymphadenopathy); chills, fever, exhaustion, headache, backache, and muscle aches are initial symptoms.
Oral lesions The oral mucosa among 70% of cases are affected as macules and vesicles; lips can be affected too
Rash Begins on the face usually, then reaches to other parts of the body; forms a scab eventually that falls off.
Beginning of a fever 1 to 5 days (before rash)
Period of symptoms 2-4 weeks
Isolation 21 days, avoiding contact with immunosuppressed individuals, pregnant individuals, and children under 12 years old.
Diagnosis Electron microscopy, virus isolation, and the PCR (polymerase chain reaction) test are the gold standard methods to confirm the MPXV infection, but most of cases in remote settings can be clinically diagnosed.
Recommendation of vaccines for health care workers (HCWs) Desirable for HCWs in monkeypox-endemic areas or during an outbreak
Prevention Traditional smallpox vaccines are useful for monkeypox; a vaccine approved for preventing monkeypox is available based on the strain of the vaccinia virus.
Table 3. Suspected transmission modes of MPX to humans.
Table 3. Suspected transmission modes of MPX to humans.
Suspected transmission modes Transmission approaches
Animal-to-human Transmission
  • Hunting, cooking, and consuming infected animals
  • Blood or body fluids
  • Scratches/bites from infected animals
  • Contact with cutaneous/mucosal lesions
Human-to-human Transmission
  • Respiratory droplets
  • Close contact
  • Direct contact with cutaneous lesions
  • Recently contaminated surfaces or objects
Table 4. Diagnosis and tests for MPXV or OPXV.
Table 4. Diagnosis and tests for MPXV or OPXV.
Tests Description
PCR (including RT-PCR) Test for the specific DNA signatures of MPXV
Electron microscopy Imaging of a brick-shaped particle for the poxvirus classification
Immunohistochemistry Test for the specific antigens of OPXV
Viral culture/isolation Live virus grows and is featured from a patient specimen
Anti-OPXV IgG Test for the antibodies of OPXV
Anti-OPXV IgM Test for the antibodies of OPXV
Tetracore OrthopoxBioThreat Alert testing for the antigens of OPXV
Table 5. Diagnostic methods of identifying human MPX.
Table 5. Diagnostic methods of identifying human MPX.
Based on Pros Cons
Phenotypic methods Clinical diagnose Possible diagnosing according to clinical signs is necessary to uncover suspected cases during examination Research on 645 individuals with clinical diagnosis of MPX (not accompanied by a lab verification) indicates a high sensitivity (93–98%) and low specificity (9%–26%).
Genetic methods PCR or qPCR
  • PCR is a standard method of finding MPX-specific DNA sequences owing to its high sensitivity and accuracy.
  • Suggested testing samples are from cutaneous lesions or a biopsy when possible.
  • High-cost tools, reagents, and skilled techniques are needed.
  • Highly sensitive examinations due to a concern about sample contamination.
Electron microscopy Electron microscopy
  • Provides testimony that MPX is of the Poxviridae family.
  • Differentiate orthopoxvirus from herpes simplex virus.
 Orthopoxviruses cannot be distinguished from each other, requiring additional diagnosis.
Immunological methods
  • Delicate discovery of IgG or IgM antibodies fighting MPX through the Elisa test.
  • Immunohistochemical (IHC) to detect virus antigens
  • Increase of anti-viral antibodies and T-cell activation fighting MPX are reported with the illness beginning.
  • At the time of the development of a rash, IgG and IgM are detectable in serum around 5 days and more than 8 days in a row.
  • An indirect diagnosis can be found if both IgG and IgM exist in unvaccinated people who have a rash history and symptoms of severe disease.
 The above approaches are not regard as qualitative ones for human MPX.
Table 6. Features of IMVAMUNE.
Table 6. Features of IMVAMUNE.
Characteristics Potential adverse events
  • Developed for people with increased risk factors for adverse events.
  • No lesion is produced at the site of vaccination; a risk of autoinoculation, inadvertent transmission, or systemic spread is no longer presented.
  • Derived from Modified Vaccinia Ankara which is a vaccinia virus with a loss of the ability to replicate in mammalian cells.
  • Local symptoms and signs, for example, pain, swelling, induration, erythema, and pruritus at the administration site.
  • Systemic symptoms and signs have been documented, for example, nausea, fatigue, headache, chills, pyrexia, and myalgia.
Table 7. Management of people with MPX and HIV infection.
Table 7. Management of people with MPX and HIV infection.
Patient groups & treatments Precautions/ recommendations Availability/effectiveness in the treatment of MPX
MPX management for people with HIV
Cidofovir (Vistide)



Tecovirimat (TPOXX, ST-246)




Vaccinia immune globulin intravenous


Brincidofovir (CMX001, Tembexa)
Contraindicated if serum creatinine >1.5 mg/dL.


Review potential interactions with antiretroviral therapy (ART).

May be thought in severe cases.


May increase serum transaminases and bilirubin.
Available from SNS
Effectiveness in the treatment of
MPX unknown

Available from SNS
Oral and intravenous formulations available


Available from SNS
Effectiveness in the treatment of
MPX unknown

Not available from SNS
Effectiveness in the treatment of
MPX unknown
HIV management for people with MPX
Newly diagnosed HIVKnown HIV


infection




HIV postexposure prophylaxis


HIV pre-exposure prophylaxis
Begin ART as soon as possible.

Keep on ART and opportunistic infection prophylaxis, as designated.

Keep on treatment or begin as designated.

Keep on treatment or start as designated.
Not applicable


Not applicable




Not applicable


Not applicable
MPX postexposure prophylaxis
JYNNEOS vaccine
Safety and immunogenicity similar in people with or without the HIV infection.		 Available data are limited,
may prevent infection if administered ≤ 4 days after exposure;
may reduce disease severity if administration ≥5 days after exposure and infection happens.
MPX pre-exposure prophylaxis
JYNNEOS vaccine
Safety and immunogenicity similar in people with or without the HIV infection.
Licensed for preventing
orthopoxvirus infections, such as
MPX
Table 8. A 3I tool of MPX 2022 for EMS professionals.
Table 8. A 3I tool of MPX 2022 for EMS professionals.
3I Description



Identify
  • Signs and symptom such as chill, fever, backache, etc.
  • Exposure
  • Ø Contact with individual(s) with suspected or confirmed MPX.
  • Ø Contact with individual(s) with rash consistent MPX.
  • Ø Attended a large party that included sex with multiple partners.
  • Ø Multiple or anonymous sexual partners.
  • Ø Contact with animals with suspected MPX.
  • Ø Travel within 21 days to a region with endemic MPX.



Isolate
  • Don personal protective equipment (PPE): N95 respirator/ equivalent (or higher), gown, gloves, eye protection, and shoe covers (if available).
  • Cover patient lesions and rashes.
  • Put a surgical mask on the patient.
  • Avoid aerosol-generating procedures.
  • Carefully discard stretcher covers.
  • Disinfect contaminated surfaces.

Inform
  • Agency’s infection-control officer.
  • Receiving facility’s healthcare staff.
  • Local health department (if the patient was not transport).
Table 9. MPX surgical safety recommendations.
Table 9. MPX surgical safety recommendations.
Outpatient care or in emergency services/preoperative Operating theaters After surgery and hospitalization
  • Appropriate use of personal protection elements
  • Diagnosis in time for suspicious patients
  • Completed medical history, looking for the signs of skin lesions or flu
  • If a person is a confirmed infection case, it ought to be assessed with the surgeon to take into account the relevance of the procedure
  • Exclusive office for the care of people confirmed with Monkeypox.
  • The procedure needs to be monitored in person or virtually in case a patient’s situation is not an emergency.
  • Only necessary personnel
  • Minimally invasive procedures
  • Decrease in surgical times
  • Sufficient disinfection for the surgical environment before & after the procedure
  • Sufficient use of personal protection elements
  • The entry of visitors will be considered according to institutional & national health regulations
  • Appropriate use of personal protection elements
  • Reduction in the hospital stay
  • Hospitalization in single-person rooms or sufficient patients’ classification with/without a diagnosis of MPX
  • Recommendation and direction for departure
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated